About
OSI Pharmaceuticals strives to improve the health and quality of life for patients, develop breakthrough treatment options for physicians, offer rewarding careers to employees, and deliver value to our shareholders. The strategy is to build on the success of our flagship product, Tarceva® (erlotinib), and continue to invest in clinical and pre-clinical drug candidates in oncology, diabetes and obesity to provide longer-term growth. OSI has evolved to become a scientifically strong and financially successful top-tier biopharmaceutical company that is focused on disease areas that impact virtually every family in the world. The Oncology team is dedicated to the discovery and development of molecular targeted therapies to revolutionize the way cancer is treated and improve treatment outcomes. The Diabetes & Obesity team is dedicated to the discovery and development of novel drugs for the treatment of type 2 diabetes and obesity. The strategy for this business team is to advance a pipeli
Position in the VCSift Database
- • 3,884 investors in VCSift focus on the healthtech sector.
- • 2 investors are based in Farmingdale, New York, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Stages
- series-a
- Sectors
- healthtech
- Location
- Farmingdale, US
Contact Information
Find more investors like OSI
Search Investors